Abstract

Background: It is widely accepted that hypertension is a pro-inflammatory disease and that the immune system plays a vital role in mediating hypertensive outcomes, end organ damages and modulation of hypertensive pathology [2]. Patient with MetS usually present increased levels of C-reactive protein (CRP) which is a prototypic marker of inflammation [5], however the data of the influence of increased levels of CRP on the control of the arterial hypertension in patients with MetS, are scarce.

Objective: We sought to determine the increased CRP levels influence on the control of the arterial hypertension in patients with MetS.

Methods: We conducted a multicenter observational cross-sectional study. The study population recruited from a couple of outpatient clinic between June 2018 and June 2019. The population study consisted of 420 patients with MetS aged ≥ 18 years, divided in two groups: 211 with level of CRP > 3 mg/l and 209 participants with CRP level < 3 mg/l.

Results: Among those with CRP level > 3 mg/l (N = 211) controlled BP according to evidence and current guidelines, was achieved in 23.6% of participants, whereas among those with CRP level < 3 mg/l (N = 209) controlled BP was achieved in 48.3%; p = 0.000). There was independent association of CRP levels > 3 mg/l with uncontrolled BP (OR = 3.1, 95%CI 2.06 - 4.75). There were significant association of uncontrolled BP with: uncontrolled glycemia (OR = 1.4, 95%CI 0.97 - 1.84); increased BMI (OR = 4.4; 95%CI 3.02 - 4.05) and five risk factors for MetS (OR = 2.3, 95%CI 1.93 - 2.81).

Conclusion: We think, we brought some good evidence, in our present study, that patients with MetS and higher CRP level have a higher prevalence of uncontrolled BP.

Keywords: C-Reactive Protein; Control of BP in Patient with Metabolic Syndrome

References

1. “Heart Disease and Stroke Statistics-2019. Update: a report from the American Heart Association”. Circulation 139 (2019): e56-528.
2. Tomasz P., et al. “Adaptive Immunity in Hypertension”. Current Hypertension Reports 21 (2019): 68.
3. Ford ES. “Prevalence of the Metabolic Syndrome Defined by the International Diabetes Federation among adults in the U.S”. Diabetes Care 28.11 (2005): 2745-2749.
4. Ford ES., et al. “Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US”. Journal of Diabetes 2.3 (2010): 180-193.
5. Haffner SM. “The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease”. The American Journal of Cardiology 97.2A (2006): 3A-11A.
6. Bryan Williams., et al. “2018 ESC/ESH Guidelines for the management of arterial hypertension”. European Heart Journal 39.33 (2018): 3021-3104. 
7. America Diabetes Association. “Standards for medical care for patient with diabetes mellitus”. Diabetes Care 25.1 (2002): S33-S49.
8. Center for disease control/American Heart association Workshop on inflammatory Markers, and Cardiovascular Disease: Application to clinical and public health practice: Atlanta, Ga. Centers for Disease Control and Prevention (2002).
9. Ford ES., et al. “Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US”. Journal of Diabetes 2.3 (2010): 180-193.
10. Organisation WH. “Waist circumference and waist -hip ratio: report of WHO expert consultation”. Geneva (2008): 8-11.
11. Guzik TJ., et al. “Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction”. Journal of Experimental Medicine 204 (2007): 2449-2460.
12. Pruijm M., et al. “Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus Study”. Journal of Human Hypertension 27 (2013): 169-175.
13. Sesso HD., et al. “C-reactive protein and the risk of developing hypertension”. Journal of American Medicine Association 290 (2003): 2945-2951.
14. Grundy SM. “Inflammation, hypertension, and the metabolic syndrome”. Journal of American Medicine Assocaition 290.22 (2003): 3000-3002.
15. Smith GD., et al. “Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality”. Arteriosclerosis, Thrombosis, and Vascular Biology 25 (2005): 1051-1056.
16. Kjeldsen SE., et al. “Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey”. Journal of Hypertension 26 (2008): 2064-2070.
17. Jani Y., et al. “Control of Arterial Hypertension among type-2 Diabetics”. International Journal of Biomedicine 3.4 (2013): 232-239.
18. Arcucci O. et al. “Association of suboptimal blood pressure control with body size and metabolic abnormalities”. Journal of Hypertension 25 (2007): 2296-2300. 
19. Garcia VP., et al. “Sex differences in High Sensitive C-Reactive Protein in subjects with Risk Factors of Metabolic Syndrome”. Arqquivos Brasileiros Cardiologia 106.3 (2016): 182-187.
20. Ridker PM., et al. “Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?”. Circulation 109 (2004): 2818-2825.
21. Sandhu HS., et al. “A Study of Correlation between Lipid Profile and Body Mass Index (BMI) in Patients with Diabetes Mellitus”. Journal of Human Ecology 24 (2008): 227-229.
22. Matsuda M and Shimomura I. “Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer”. Obesity Research and Clinical Practice 7 (2013): E330-E341.